Form 4: Immix Biopharma Director Acquires 33,000 Stock Options

Yekaterina Chudnovsky, a director of Immix Biopharma, Inc., acquired 33,000 stock options on June 11, 2024.

Summary

• On June 11, 2024, Yekaterina Chudnovsky, a director of Immix Biopharma, Inc., acquired 33,000 stock options with an exercise price of $2.04.
• These options vest in twelve equal monthly installments, contingent upon her continued service on the Board of Directors.
• Chudnovsky also indirectly owns 3,241,076 shares of common stock through GKCC, LLC, where she is the sole member and manager.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of stock options by a director is generally viewed as a positive, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service on the Board of Directors, suggesting an ongoing commitment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the beneficial ownership of Immix Biopharma's securities by a director.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biopharmaceutical industry to align their interests with those of shareholders.
• The vesting schedule of twelve equal monthly installments is a fairly standard approach.
• Comparing the size of the grant (33,000 shares) to similar companies would require further analysis of Immix Biopharma's compensation policies and market capitalization.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates